Two treatments dominate the evidence for androgenetic alopecia, the most common cause of hair loss: a 2017 systematic review found topical minoxidil produced modest but significant hair-count gains versus placebo, and meta-analyses of finasteride trials reported roughly 87 percent of men improved or stabilized over two years, per data supporting its FDA approval in 1997.
Newspaper Daily publishes information, not medical advice. This article summarizes what research and regulators report about hair loss treatments; it does not diagnose the cause of anyone's hair loss or recommend prescriptions, and hair loss has multiple medical causes that warrant professional evaluation before treatment decisions.
Why does identifying the cause come first?
Androgenetic pattern loss, the gradual thinning driven by genetics and hormone sensitivity, is only one mechanism. Telogen effluvium, a temporary shedding weeks to months after illness, childbirth, rapid weight loss, or new medications, reverses when the trigger resolves and may respond poorly to pattern-loss drugs. Alopecia areata is autoimmune and treated differently, and thyroid disease, iron deficiency, and traction damage produce their own patterns. Dermatology reviews consistently note that starting pattern-loss medication for the wrong condition wastes months and delays diagnosis, which is why evaluation precedes treatment in clinical guidance.
What does the evidence show for minoxidil?
Minoxidil 2 percent was the first FDA-approved topical for hair loss, converted to nonprescription status in 1996, with a 5 percent formulation following over the counter. Randomized trials in men and, later, in women found increased hair counts and subject-rated growth versus placebo at 16 to 48 weeks, with effects modest in magnitude and dependent on continued use: discontinuation reverses gains within months, an outcome trials documented directly. The 5 percent foam became the standard strength for men, and 5 percent solutions or once-daily 5 percent foam are studied in women, where higher-strength solution caused more unwanted facial hair in trials. Oral low-dose minoxidil, an older blood-pressure drug repurposed off-label at 0.625 to 5 milligrams, has accumulated promising case series and growing trial data since 2017, though reviews call large randomized studies still lacking.
What about finasteride and other prescription drugs?
Finasteride 1 milligram daily blocks the conversion of testosterone to dihydrotestosterone, the hormone driving follicle miniaturization. The FDA approved it for male pattern loss in 1997, and meta-analyses report hair-count improvements and slowed progression over two to four years. Its labeling carries sexual-side-effect warnings and, since 2011, an FDA safety communication about possible mood changes; the agency in 2025 added broader risk language pending review. Dutasteride, a stronger relative, holds approval for hair loss in South Korea and Japan and has supportive randomized trials elsewhere. For women, spironolactone is prescribed off-label with observational and small trial support, and combined oral contraceptives help some hormonal-pattern cases.
Do laser combs, caps, and PRP work?
Low-level laser therapy devices received FDA clearance as devices, a standard covering substantial equivalence rather than the efficacy trials required of drugs. Available randomized trials are small and short, with several reporting increased hair density versus sham devices and reviewers judging the evidence modest and industry-linked. Platelet-rich plasma injections show a similar profile: multiple small randomized trials and a 2020s meta-analysis report density improvements versus placebo or no treatment, but injection protocols vary widely, blinding is difficult, and studies are short. Neither approach has head-to-head trials against minoxidil or finasteride of the scale the leading drugs have.
Related stories: Retinoids for Skin: What the Evidence Actually Supports · Acne Treatments: What the Research Shows Works.
What about supplements and biotin?
The supplement evidence is weakest of all. Biotin deficiency causes hair changes, but reviews note true deficiency is rare, and trials of biotin in people without deficiency are essentially absent; a 2017 review found no evidence supporting biotin for hair in healthy people and warned it can interfere with laboratory tests, prompting an FDA safety communication in 2017. Small trials of marine-protein extracts and pumpkin seed oil showed positive signals in single studies with industry involvement. Supplements sold in the United States are not FDA-reviewed for efficacy before marketing.
How do the options compare at a glance?
| Option | Evidence tier | Regulatory status in the US | Key caveat |
|---|---|---|---|
| Topical minoxidil | Multiple randomized trials, meta-analyzed | OTC drug | Gains reverse after stopping |
| Finasteride 1 mg | Multiple randomized trials, meta-analyzed | Prescription drug | Boxed safety warnings in labeling |
| Low-level laser devices | Small short trials | Device clearance | Clearance is not efficacy approval |
| PRP injections | Small trials, meta-analyses emerging | Procedure, not separately approved | Protocols vary; studies short |
| Biotin and hair supplements | Lacking without deficiency | Dietary supplement | Not FDA-reviewed for efficacy |
Does hair transplant surgery have evidence?
Transplantation relocates follicles resistant to hormonal miniaturization from the back of the scalp to thinning zones, and long-term observational series document durable results. Reviews position surgery as a structural solution for stable pattern loss rather than a treatment of the underlying process, and studies note transplanted hair does not protect existing follicles, which is why clinicians often pair surgery with medication. Candidate selection and surgeon skill dominate outcomes in the published series.
Can shampoo or scalp care regrow hair?
Ketoconazole shampoo has small studies suggesting modest adjunctive benefit, possibly anti-inflammatory, with no trial support as a standalone regrowth treatment. Caffeine shampoos rest on laboratory and single small trials. Hair loss is a follicle-level process that surface products reach weakly, a limitation reviews repeat for most scalp-care marketing.
Can hair loss be prevented?
Prevention advice tracks the causes. Traction alopecia from tight hairstyles is largely avoidable, and dermatology case series show early traction loss reverses while prolonged tension scars follicles permanently. Treating iron deficiency or thyroid disease protects hair when those conditions are present. For pattern loss, reviews describe early intervention as sensible rather than preventive in a strict sense, since follicle miniaturization starts years before thinning is visible and trials enroll people with measurable loss. No supplement, shampoo, or scalp procedure has trial evidence for preventing pattern loss in people without it.
When should someone see a dermatologist?
Evaluation is warranted for sudden or patchy loss, shedding that began after illness or new medication, loss accompanied by scalp symptoms such as itching, scaling, or pain, thinning before adulthood, or any pattern suggesting a medical cause. A clinician can distinguish pattern loss from alopecia areata, telogen effluvium, scarring conditions, and thyroid or iron-related causes, some of which are reversible when caught early. Anyone experiencing mood changes or sexual side effects while taking finasteride should contact the prescribing clinician, per FDA safety communications.
Bottom line
The trial record for hair loss is narrow but firm at its center: topical minoxidil and oral finasteride carry decades of randomized evidence for pattern loss, both requiring ongoing use, while lasers, PRP, and supplements offer smaller or weaker data. Diagnosis first, then treatment, remains the sequence the research supports.